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Int J Geriatr Psychiatry. 2018;33:663–670.Objective: To investigate the effects of pain treatment on sleep in nursing home (NH)
patients with dementia and depression.
Methods: A multicenter, 2‐armed, double‐blinded, placebo‐controlled, randomized clinical
trial conducted between August 2014 and September 2016. One hundred six long‐term patients
from 47 NHs in Norway with dementia and depression according to the Mini‐Mental State
Examination and the Cornell Scale for Depression in Dementia were included. Patients received
stepwise pain treatment in which those who did not use analgesics were randomized to receive
either paracetamol (3 g/day) or placebo tablets; those who already used pain treatment were
allocated to buprenorphine transdermal system (max. 10 μg/h/7 days) or placebo transdermal
patches. Sleep was assessed continuously for 14 days by actigraphy, 1 week of baseline
measurement, and 1 week of ongoing treatment. The following sleep parameters were evaluated:
total sleep time, sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset, early
morning awakening (EMA), and number of wake bouts.
Results: In the intervention group (paracetamol/buprenorphine), SE (70%‐72%), SOL
(32‐24 min), and EMA (50‐40 min) improved compared with the control group (SE, 70%‐67%;
SOL, 47‐60 min; EMA, 31‐35 min). Treatment effects were significant (P < .01, P < .05, and
P < .05, respectively).
Conclusion: Compared with placebo, pain treatment improved sleep as measured with
actigraphy. This implies that sleep, pain, and depression in NH patients should be critically
evaluated and that pain treatment should be considered to be a potentially beneficial treatment.
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Approximately 60% of nursing home (NH) patients experience nightime
sleep disturbances,1,2 and 50 to 80% of NH patients have dementia.3-5
Previous studies have reported that NH patients with dementia have
more disturbed nightime sleep compared with NH patients without
dementia.6 The capacity to maintain either sleep or wakefulness is fur-
ther impaired as dementia progresses.6 Sleep disturbances among NH
patients can be attributed to medical disorders, polypharmacy,7 pain,8,9- - - - - - - - - - - - - - - - - - - - - - - - - - -
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d, the use is non‐commercial and
tric Psychiatry Published by John Wand depression.2,10 Sleep disturbances in this population may have
serious consequences, as they increase the risk of falls11 and hip
fractures,12,13 decrease survival,14 and impair daytime functioning (eg,
reducedmemory, concentration, reaction time, and loss of autonomy).15
Studies indicate that approximately 20 to 30% of NH patients have
depression.16 The close interrelation between pain and depression is
often referred to as the pain‐depression dyad.17 This implies that both
conditions share common signal pathways and neurotransmitters and
that they are responsive to comparable treatments.17 Depression is also- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Key points
• Sleep disturbances are very common among people with
dementia.
• Compared with placebo, pain treatment improved sleep
in NH patients with dementia and depression, as
measured by actigraphy.
• Sleep, pain, and depression in NH patients should be
evaluated systematically, and pain treatment should be
considered as a potentially beneficial treatment.
664 BLYTT ET AL.associated with sleep disturbances, especially among people with cog-
nitive impairment.18,19 Previous research suggests overlapping neural
networks for depression, sleep disturbance, and dementia.20 Among
various neuropsychiatric symptoms, sleep and depressive symptoms
are often considered to coincide as a “mood‐cluster.”21
Pain represents an important cause of poor sleep for people with
and without dementia.22 Previous studies indicate that there is a
bidirectional relationship between pain and sleep disturbances.23
Approximately 60% of NH patients experience pain every day.24 The
prevalence may vary, however, as pain can be difficult to evaluate in peo-
ple with dementia, who have reduced ability to describe their symptoms.
It is therefore important that NH staff seek to identify pain through
appropriate methods25 and exclude pain as a factor contributing to sleep
disturbances before prescribing sleep medications. Overall, the presence
of pain, dementia, and depression, together with sleep disturbances, may
lead to a downward spiral regarding health and well‐being.15,19
In a cluster‐randomized clinical trial conducted by Husebo et al,26
a stepwise protocol of treating pain was found to improve mood, sleep,
and depression in people with dementia and agitation. The study did,
however, not include objective sleep measurements and was not
placebo‐controlled. Consequently, the aim of the present study was
to investigate the effect of pain treatment on sleep in NH patients with
dementia and depression in a placebo‐controlled randomized clinical
trial with objective sleep measurements.
We hypothesized that pain treatment would improve total sleep
time (TST), sleep efficiency (SE), sleep onset latency (SOL), waking after
sleep onset, early morning awakening (EMA), and number of bouts
awake. In addition, we conducted several subgroup analyses. In 1 sub-
group analysis, the aim was to investigate the effects of pain treatment
on different sleep outcomes for patients with poor sleep at baseline,
defined as SE < 85%. In a second analysis, the aim was to investigate
if pain treatment improved sleep more in patients who were in pain
at baseline, defined as Mobilization‐Observation‐Behaviour‐Intensity‐
Dementia‐2 Pain Scale (MOBID‐2) score ≥ 3. In a final analysis, we
aimed to investigate if there were any differences within the active
treatment group, ie, between patients receiving active buprenorphine
and active placebo, respectively.2 | METHODS
This study used data collected in the period from 1 week before the
intervention until 1 week after the intervention. The study is part of
a 13‐week, multicenter, parallel‐group, double‐blind, placebo‐con-
trolled randomized trial: “Efficacy of Pain Treatment on Depression in
Patients with Dementia—A Randomized Clinical Trial of Efficacy:
DEP.PAIN.DEM.” The study was conducted in Norway from August
2014 to September 2016.
The NHs were located in 11 municipalities in both urban and rural
areas and both larger and smaller Norwegian towns. Data collection
was conducted by 2 researchers, who recruited NHs through direct
contact with NH management. Inclusion and exclusion criteria are
listed in Table 1. At the participating NHs, the researchers were
granted access to patient medical records to perform prescreening. In
cases where no recent (<14 days old) blood analyses (electrolytes,hemoglobin, serum creatinine, and serum alanine aminotransferase)
were available, new analyses were requisitioned. Patients who were
not excluded in the medical record review were screened for depres-
sion by using the Cornell Scale for Depression in Dementia (CSDD)27
and for dementia by using the Mini‐Mental State Examination
(MMSE).28 If the inclusion criteria (CSDD ≥ 8 and MMSE < 20) were
fulfilled, the patient was reassessed after written consent had been
given. A drop from ≥8 to ≥6 in CSDD was permitted between screen-
ing and baseline. If a patient fulfilled all of the inclusion criteria and
none of the exclusion criteria, and inclusion and study treatment were
approved by the physician responsible for the patient, the patient was
enrolled in the study (see the flow chart in Figure 1 for an overview of
enrolment and reasons for exclusion).
A fixed‐dose regimen was used in the study period. The patients
were offered a 1‐g tablet/placebo at breakfast, lunch, and supper
(8 a.m. noon and 6 p.m.). The patients received a stepwise pain treat-
ment, in which those who were taking paracetamol ≤1 g/day prior to
inclusion were allocated to paracetamol tablets/placebo tablets. The
study treatment was prescribed in addition to the basic dose. Patients
who were taking nonopioid analgesics/paracetamol >1 g/day, and/or
NSAID/buprenorphine, but had difficulty with swallowing tablets were
assigned to the buprenorphine/placebo transdermal system. In line
with the administrative guidelines, the buprenorphine transdermal
patch/placebo patch was changed on a fixed day every week. For
patients who were taking buprenorphine transdermal 5 μg/h prior to
inclusion, the study treatment was given as an additional 5‐μg/h trans-
dermal patch (active or placebo). After inclusion, all patients continued
their usual medical treatment (including any regular or “as needed”
[PRN] analgesic). To ensure stability and control in the study, the
clinicians were advised to keep doses of psychotropic and analgesic
drugs unchanged during the study period. If any clinical changes
occurred, eg, new conditions or injuries, they were to be treated ade-
quately. All withdrawals and reasons were registered.
All sleep‐related outcomes were assessed with Actiwatch
Spectrum (Philips Respironics). Activity was registered continuously
for 14 consecutive days, during which the intervention started on
day 8. Data were thus recorded for all sleep parameters for duration
of 1 week before and 1 week after the study treatment commenced.
The actigraphs were placed on the dominant/mobile wrist. To enable
better scoring of the patients' actual time spent in bed, the NH staff
were instructed (verbally and written) to register bedtimes and rising
times by pushing the event button on the actigraph (light off/lights on).
FIGURE 1 Flow chart screening and inclusion
2323 patients from 47 NHs 
screened for eligibility
137 did not consent
562 took opioid analgesics (5 µg/h buprenorphine
transdermal prior to inclusion was permitted)
895 did not have depression (CSDD < 8)
99 had blood tests indicating renal/hepatic failure or anemia
56 had life expectancy less than 6 months
139 did not have dementia (MMSE 20)
54 died prior to enrolment
65 had a psychiatric disorder which warranted exclusion
87 had short-term placement or moved
14 had allergy to study treatment
30 were under 60 years of age
14 due to changes in psychotropic drugs
9 due to other reasons 
Enrolled in the main study:
162
Actigraphy sub-project:
7 had Parkinson’s disease
11 did not consent
8 removed the actigraph
30 other reasons (incl. missing 
data, malfunctioning actigraphs, 
etc.)
Enrolled in the sleep 
sub-project:
106
57 active treatment 49 placebo
TABLE 1 Inclusion and exclusion criteria in the actigraphy subproject
Inclusion Criteria Age ≥ 60 years
Long‐term nursing home placement with >4‐week stay
Dementia (MMSE ≤ 20)
Depression (CSDD ≥ 8, >3‐week duration)
Exclusion criteria Life expectancy < 6 months
Severe medical disease that could interfere with study participation
Severe liver and/or renal impairment
Anemia (Hb < 8.5 mmol/L) or electrolyte imbalance (Na+ and K+)
Suicide risk (any attempts during the last year)
History of severe psychiatric disease prior to dementia onset
Severe aggression (NPI‐NH aggression item score ≥ 8, with aggression as the predominant symptom)
Severe pain (MOBID‐2 ≥ 7)
Uncontrolled epilepsy
Contraindication or clinically significant drug interaction to the assigned study treatment
Change in psychotropic drugs
Regular use of any opioid analgesic other than, or exceeding, buprenorphine 5 mcg/h
Did not want to wear an actigraph
Immobile patients (paralysis, or otherwise bedridden)
Patients with involuntary movement (eg, Parkinson disease)
Less than 5 nights of actigraphy recordings
Abbreviations: CSDD indicates Cornell Scale for Depression in Dementia; MMSE, Mini‐Mental State Examination; MOBID‐2, Mobilization‐Observation‐
Behaviour‐Intensity‐Dementia‐2 Pain Scale; NPI‐NH, Neuropsychiatric Inventory‐Nursing Home Version.
BLYTT ET AL. 665The Actiware 6 (Respironics) was used for sleep scoring. Sensitivity
was set to medium, and sleep/waking status was determined for each
1‐minute epoch. A trained technician scored all the activity protocols.
A standardized hierarchical approach was used to set rest intervals
for the actigraphy data, using (1) event markers when possible, or (2)
light and activity data, or (3) light or activity data. Alternatives 2 and3 were only implemented if there was a clear differentiation between
active and rest periods; if not, the actigraphy protocol was excluded.
Depression was assessed by using the validated CSDD. The CSDD
consists of 19 items measuring 5 domains of depression (mood, behav-
ioral disturbances, physical signs, cyclic functions, and ideational distur-
bances). A cut‐off point of 8/9 has demonstrated the best accuracy for
666 BLYTT ET AL.diagnosing depression according to the International Statistical
Classification of Diseases and Related Health Problems 10th Edition
criteria.27 The assessment was conducted by using only information
provided by NH staff members who knew the resident very well.
Pain was assessed by the MOBID‐2, a validated staff‐administered
instrument for measuring pain in people with advanced dementia.25
The instrument provides a total score based on all of the observations
ranging from 0 to 10, where 10 represents the worst possible pain.25 A
score of ≥3 has been used as a cut‐off to indicate clinically relevant
pain.25
Cognitive function was assessed by using the validated MMSE.28
The MMSE is a brief, cognitive screening test with a 30‐point scale
that consists of 20 tasks and was developed to distinguish potential
dementia from normal functioning.29 Five patients started the MMSE
screening and scored very poorly and subsequently withdrew from
the MMSE screening. This led to missing data. For these patients,
cognitive function was assessed by proxy through conversations with
primary doctors and nurses as an alternative to MMSE screening.
The patients were randomly allocated to each arm in a 1:1 ratio,
using computer‐generated random numbers. The randomization list
was produced by a statistician, without any involvement of the
research team. There was no use of stratification factors. The research
team was provided with a blinded, sequential list of pack identification
numbers, and the patients were consecutively assigned to the next
pack number in the list upon inclusion. The study was double‐blinded,
and all researchers, patients, and NH staff were masked regarding the
group allocation.
Descriptive statistics were calculated for all relevant variables.
Comparisons of sleep parameters pre‐ and posttreatments were per-
formed as a mixed within‐between subjects ANOVA (placebo versus
active treatment and pretreatment versus posttreatment). Differences
between pre‐ and posttreatments within each treatment group were
assessed with paired t tests for each of the experimental groups
separately. Furthermore, we conducted additional 2 × 2 mixed
within‐between subjects ANOVA analyses. One of these analyses
investigated patients who had sleep disturbances at baseline, defined
as SE < 85%,30 and compared the effect of active and placeboTABLE 2 Within‐ and between‐group effects of the placebo and active tr
Placebo Group (n = 49) Acti
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mea
TST (min) 509.9 (113.6)‐498.8 (126.5) .164 0.20 515
SE (%) 70.0 (13.1)‐67.5 (14.8) .036 0.31 69.9
SOL (min) 47.0 (44.5)‐59.6 (80.3) .187 0.19 31.7
WASO (min) 140.6 (68.3)‐143.3 (68.3) .610 0.07 136
EMA (min) 30.7 (38.9)‐35.2 (35.5) .268 0.16 50.1
NoW (no.) 31.2 (11.6)‐30.3 (11.8) .404 0.12 30.0
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset laten
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tes
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and ac
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.treatments for those patients. A second analysis compared the effect
of the treatments for a subgroup of patients whose MOBID‐2 score
was ≥3, ie, patients who had pain at baseline. The last analysis investi-
gated patients in the active treatment group and thus compared the
effect of active buprenorphine to that of active paracetamol. The
statistical analyses were conducted by using IBM SPSS Statistics 22.
Each patient's medical decision‐making capacity was discussed
with the patient's primary nurse at the NH. Attempts were made to
adjust the information for patients who had reduced capacity to give
consent (MMSE score from 16 to 19).31 In addition, the researchers
contacted all of the eligible patients' legal guardians. If the legal guard-
ians gave presumed consent on behalf of the patient, they received
written and oral information together with a consent form that they
signed and mailed back. The study was approved by the Regional
Ethics Committee (REC‐West 2013/1474). The study's clinical trial
number is NCT02267057.3 | RESULTS
In total, 2323 patients were screened for eligibility, of whom 162 were
eligible to participate as part of the broader study. The final sample of
the actigraphy subproject included 106 participants (see Figure 1). Of
the 106 patients, 49 were randomly assigned to the placebo group
and 57 to the active treatment group. In the active treatment group,
2 patients dropped out due to their reaction to the treatment. In the
total sample of patients with actigraphs, the mean age was 85.5 years
(SD = 7.3), 76%were female, themean CSDD scorewas 11.2 (SD = 3.7),
the mean MMSE score was 7.6 (SD = 6.0), the mean MOBID‐2 score
was 2.8 (SD = 2.1), and 54.7% had a MOBID‐2 score ≥ 3. Sleep charac-
teristics pre‐ and posttreatments for patients in both experimental
groups, as well as the interaction effect for each sleep outcome, are
shown in Table 2.
In the total sample (n = 106), SE, SOL, and EMA all improved for
the active treatment group compared with the placebo group (see
Table 2). The analysis of the treatment for the subgroup of patients
with preexisting sleep disturbances (SE < 85%) identified at baselineeatments on different sleep outcomes
ve Group (n = 55) Interaction Effectc
n (SD) Pre*‐Post** P Valuea Effect Sizeb F value P Value
.6 (136.7)‐526.9 (119.7) .235 0.16 3.25 .074
(14.8)‐72.2 (12.5) .039 0.29 9.11 .003
(35.2)‐24.6 (28.2) .079 0.24 4.03 .047
.0 (66.7)‐134.5 (58.2) .800 0.03 0.27 .604
(61.1)‐40.5 (37.5) .082 0.24 4.20 .043
(11.9)‐29.4 (13.5) .551 0.08 0.05 .831
cy; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
ts for the placebo group and the active group).
tive treatments.
TABLE 3 Effects of the placebo and active treatments on different sleep outcomes for patients with SE < 85%
Group With SE Below 85% (n = 89)
Placebo Group (n = 44) Active Group (n = 45) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 488.8 (97.6)‐475.3 (108.1) .107 0.25 477.7 (114.6)‐497.6 (103.9) .065 0.28 6.25 .014
SE (%) 67.5 (11.3)‐64.9 (13.3) .049 0.30 65.4 (12.4)‐69.0 (10.8) .005 0.44 12.18 .001
SOL (min) 51.9 (44.4)‐66.0 (82.4) .182 0.20 37.3 (36.5)‐28.2 (29.7) .063 0.28 4.17 .044
WASO (min) 150.7 (63.9)‐153.5 (63.5) .635 0.07 154.4 (58.3)‐148.7 (50.3) .432 0.12 0.83 .363
EMA (min) 33.7 (40.0)‐37.2 (36.3) .418 0.12 58.5 (64.5)‐45.6 (39.1) .049 0.30 4.51 .036
NoW (no.) 31.7 (11.6)‐30.5 (11.4) .339 0.15 32.5 (10.6)‐31.5 (12.3) .365 0.14 0.00 .957
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the placebo group and the active group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients with poor sleep efficiency.
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
TABLE 4 Effects of the placebo and active treatments on different sleep outcomes for patients with pain (MOBID‐2 ≥ 3) at baseline
Group With Pain (n = 46)
Placebo Group (n = 25) Active Group (n = 21) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 518.3 (126.0)‐523.8 (130.7) .528 0.13 554.4 (141.8)‐565.2 (127.8) .223 0.27 0.18 .667
SE (%) 70.3 (14.9)‐69.4 (14.4) .330 0.20 74.1 (14.5)‐75.7 (13.6) .122 0.35 3.56 .066
SOL (min) 42.5 (44.7)‐49.5 (66.9) .413 0.17 25.1 (26.5)‐23.0 (24.9) .611 0.11 0.84 .362
WASO (min) 137.7 (67.1)‐140.4 (75.0) .737 0.07 128.2 (73.5)‐124.7 (70.4) .683 0.09 0.28 .595
EMA (min) 37.3 (51.4)‐36.7 (39.7) .906 0.02 34.0 (36.4)‐29.9 (30.2) .276 0.24 0.34 .559
NoW (no.) 31.3 (12.7)‐30.1 (13.3) .407 0.17 29.7 (14.2)‐30.5 (15.6) .623 0.11 0.88 .351
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the placebo group and the active group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the placebo and active treatments for the patients with pain (MOBID‐2 score ≥ 3).
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
TABLE 5 Effects of the placebo and active treatments on different sleep outcomes for patients given active buprenorphine and paracetamol
Group With Active Treatment (n = 55)
Paracetamol Group (n = 25) Buprenorphine Group (n = 30) Interaction Effectc
Mean (SD) Pre*‐Post** P Valuea Effect Sizeb Mean (SD) Pre*‐Post** P Valuea Effect Sizeb F Value P Value
TST (min) 531.5 (145.5)‐518.3 (131.4) .233 0.24 502.3 (129.9)‐534.0 (110.9) .029 0.42 6.176 .016
SE (%) 72.2 (14.1)‐72.4 (12.7) .854 0.04 68.0 (15.4)‐72.1 (12.6) .027 0.42 3.252 .077
SOL (min) 34.0 (35.5)‐29.0 (33.5) .238 0.24 29.8 (35.4)‐20.9 (22.8) .181 0.25 0.241 .626
WASO (min) 121.3 (63.8)‐123.6 (52.8) .762 0.06 148.3 (67.7)‐143.5 (61.7) .610 0.09 0.333 .566
EMA (min) 42.9 (47.4)‐39.7 (39.7) .562 0.12 56.1 (70.8)‐41.2 (36.2) .101 0.31 1.173 .284
NoW (no.) 28.5 (11.8)‐28.4 (13.6) .969 0.01 31.3 (12.1)‐30.2 (13.6) .464 0.14 0.244 .624
Notes: TST indicates total sleep time; SE, sleep efficiency; SOL, sleep onset latency; WASO, waking after sleep onset; EMA, early morning awakening; NoW,
number of bouts awake.
aPaired t test, comparing values before and after the intervention (separate tests for the buprenorphine group and the paracetamol group).
bEffect size (Cohen's d) for paired values.
cA mixed within‐between subjects 2 × 2 ANOVA comparing the buprenorphine and paracetamol groups for the patients who received active treatment.
*Pre = −7 to 0 days (baseline).
**Post = 1 to 7 days active/placebo treatment.
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668 BLYTT ET AL.(n = 89) confirmed the main effects (see Table 3). In addition, TST
improved significantly for the active treatment group compared with
the placebo group (see Table 3). Interestingly, when analyzing the
effect of treatment for the subgroup of patients who experienced pain
at baseline (n = 46), we found no significant differences between active
and placebo treatment for any of the sleep outcomes (seeTable 4). In a
final analysis, we investigated if there were any differences within the
active treatment group (seeTable 5). We found a significant increase in
TST for patients who received active buprenorphine compared with
those who received active paracetamol (see Table 5).4 | DISCUSSION
The results of the present study gave partial support to our hypothe-
ses. The study demonstrated that active pain treatment for people
with dementia and depression improved 3 central sleep parameters:
SE, SOL, and EMA. When we analyzed the subgroup with poor sleep
at baseline, the results were further strengthened, with an additional
improvement in TST. Moreover, the group of patients who received
the active buprenorphine transdermal patch had significantly longer
TST compared with the active paracetamol group. However, being in
pain at baseline was not associated with improved sleep after active
treatment.
To the best of our knowledge, this is the first placebo‐controlled
randomized clinical trial to investigate the efficacy of pain treatment
on sleep among NH patients with dementia and depression. The study
is of key importance for clinicians, because it provides new insight into
the complex and poorly understood relationship among pain, depres-
sion, and sleep. There is a great need for such insight, because sleep
disturbances are endemic among NH patients, and knowledge regard-
ing potential treatment is essential.
Even though the underlying mechanisms of the results are
unknown and the clinical value of the treatment effect is uncertain,
the results indicate that pain treatment may contribute to improved
sleep among some NH patients with dementia and depression. As
described above, there were patients already receiving pain medication
(paracetamol) prior to inclusion. However, our results suggest that
some of the patients might not be adequately treated, with paraceta-
mol alone or only with a low dose. Therefore, these patients may expe-
rience beneficial effects of stronger medication (eg, buprenorphine) or
an increased dose of already prescribed medication.
Interestingly, when we conducted subgroup analyses of the
patients with sleep disturbances (defined as SE < 85%), we found sig-
nificant improvement in TST in addition to SE, SOL, and EMA, indicat-
ing that the group of patients with poor sleep might derive greater
benefit from pain treatment. Husebo et al32 found that a systematic
approach to pain management significantly reduced agitation among
people with dementia and agitation. In a different study, also con-
ducted by Husebo et al,26 the results showed that mood symptoms,
including depression and sleep disturbances, improved with pain
treatment in the same patient group. This was partly attributed to
potentially untreated pain.26,32 Interestingly, in the present study, we
found no improvements in sleep in the subgroup of patients in pain
at baseline. Thus, the results do not support that the underlyingmechanism is untreated pain. It should be noted that the subgroup
analysis only included 21 patients with active treatment and pain
according to MOBID‐2. The lack of significant differences could there-
fore be due to the low sample size. It is noteworthy, however, that
Zanocchi et al33 found no association between sleep problems and
the presence of pain, although pain intensity was associated with
patients' sleep disturbances.
Furthermore, the results showed that TST increased significantly
among patients who received active buprenorphine compared with
patients who received active paracetamol. Because sedation is a
frequently reported opioid‐associated side effect, which is more likely
to occur at the onset of therapy or with dose increase,34 this may sug-
gest an opioid‐associated sedation effect. Actigraphy only records
movement, and a total lack of movement would therefore be assessed
as sleep. It is not possible to examine the question of whether there is
a sedation effect further with this study design.
In the present study, the NH patients wore the actigraph on the
dominant or mobile wrist. This choice was made because many NH
patients have limited mobility, due to medical conditions (eg, stroke
or paralysis) or general fragility and inactivity. Therefore, potential
activity would more likely to occur first in the dominant or mobile
wrist. This implies that wearing the actigraph on the dominant wrist
increases the probability of activity to be registered. There are no stan-
dards regarding the placement (dominant/nondominant wrist) of the
actigraph.35 However, in prior studies on persons with dementia, the
dominant wrist is most commonly used. For instance, Camargos
et al35 recommended using the dominant or mobile wrist. It would,
however, be valuable to assess the potential differences between
measurements on the nondominant versus the dominant wrist in
future research.
The results should be interpreted with caution because the study
design does not allow us to assess if the improvement is of subjective
value for the patient. Further research is necessary to investigate this
more extensively. However, the results of this study suggest that clini-
cians should evaluate pain, sleep, and depression by using proper
assessment tools and, based on such evaluation, consider pain treat-
ment as potentially beneficial for patients with sleep disturbances.5 | LIMITATIONS
Our study has some limitations. The use of multiple sleep‐related out-
come measures is a potential study limitation, which can potentially
lead to type I errors. We do not correct for multiple comparisons in
our study. However, a simple Bonferroni correction would be overly
conservative and would increase the risk of type II errors.36 Therefore,
we urge the reader to take the lack of such correction into account in
the interpretation of the findings of the study.
In actigraphy recordings, immobility of the participants marks the
beginning of the sleep period. Sleep onset latency has been particularly
difficult to ascertain with actigraphy, because patients may just be
lying still in bed and it can be recorded as sleep.37 In addition, previous
studies show that actigraphy is less precise in differentiating between
sleep and wakefulness when SE is reduced.37-39 Both of these factors
may lead to an overestimation of sleep.
BLYTT ET AL. 669The comprehensive combination of inclusion and exclusion criteria
made it difficult to recruit patients to the study. Of the 2323 patients
screened for potential eligibility, a total of 895 did not have depression
according to CSDD. In addition, there has been a change in the pre-
scription of pain medication for NH patients during the last decade
that influenced inclusion. Sandvik et al40 found that analgesic drug pre-
scription at NHs increased significantly from 2000 to 2011, and in par-
ticular the use of paracetamol and strong opioids. This impeded the
inclusion of patients in the study, as a high number of patients were
already taking high doses of opioids (n = 562) and could not be
included. This may have excluded some people with depression or
sleep problems, who could have benefited from the study intervention.
This renders the generalizability of our study questionable because our
sample may not be representative for the general NH population.
Furthermore, the subgroup analysis is based on a low number of
respondents, which implies that we cannot exclude type 2 errors.
Another central limitation in the study is that it does not include pain
assessment during the week after the intervention. As a consequence,
we do not know how pain progressed after the intervention. Future
research should include a larger sample of patients with pain at base-
line to account for a large attrition rate and follow‐up with pain assess-
ments after the intervention is given. A further limitation of our study
was that we did not conduct a priori power analyses, which would
have been beneficial for assessing if the statistical tests have sufficient
power. However, our sample is similar to or larger than samples
in comparable studies. The reader should, however, interpret the find-
ings with caution, in particular for the subgroup analyses with lower
sample sizes.6 | CONCLUSION
Compared with placebo, pain treatment improved actigraphy‐mea-
sured sleep in NH patients with dementia and depression. This implies
that sleep, pain, and depression in NH patients should be evaluated
critically and that pain treatment should be considered as a potentially
beneficial treatment for residents with poor sleep. Future research
should focus on the underlying mechanisms and explore the subjective
value of such treatment for the NH patient.
ACKNOWLEDGEMENTS
We thank the patients, their relatives, and the NH staff for their will-
ingness and motivation, which made this work possible. EF is granted
by the Research Council of Norway. KMB is granted by the Western
Norway Regional Health Authority. BSH would like to thank the G.C.
Rieber Foundation and the Norwegian Directorate of Health for
supporting our work at the Centre for Elderly and Nursing Home
Medicine, University of Bergen, Norway. We would also like to thank
Mundipharma International for supplying the buprenorphine transder-
mal and placebo patches with randomization lists and Kragero Tablet
Production A/S and Anne Hovstad for production of the paracetamol
and placebo tablets. We also thank Magne Solheim for generating
the paracetamol/placebo randomization lists. KMB had full access to
all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analyses.CONFLICT OF INTEREST
Mundipharma International supplied the study medication, but the
company did not influence the study design, data collection, analyses
and interpretation of data, or final publication.
ORCID
Kjersti Marie Blytt http://orcid.org/0000-0003-3074-7343
REFERENCES
1. Neikrug AB, Ancoli‐Israel S. Sleep disturbances in nursing homes. J Nutr
Health Aging. 2010;14(3):207
2. Ownby RL, Peruyera G, Acevedo A, Loewenstein D, Sevush S. Subtypes
of sleep problems in patients with Alzheimer disease. Am J Geriatr
Psychiatry. 2014;22(2):148‐156.
3. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders
among older adults in long‐term care homes: a systematic review. Int
Psychogeriatr. 2010;22(07):1025‐1039.
4. Blytt KM, Selbaek G, Drageset J, Natvig GK, Husebo B. Comorbid
dementia and cancer in patients of nursing homes: secondary analyses
of a cross‐sectional study. Cancer Nurs. In press
5. Selbæk G, Kirkevold Ø, Engedal K. The prevalence of psychiatric symp-
toms and behavioural disturbances and the use of psychotropic drugs in
Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):843‐849.
6. Pat‐Horenczyk R, Klauber MR, Shochat T, Ancoli‐Israel S. Hourly profiles
of sleep and wakefulness in severely versus mild‐moderately demented
nursing home patients. Aging Clin Exp Res. 1998;10(4):308‐315.
7. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence
and factors associated with polypharmacy in long‐term care facilities:
a systematic review. J Am Med Dir Assoc. 2015;16(6):535.e1‐12.
https://doi.org/10.1016/j.jamda.2015.03.003.
8. Flo E, Bjorvatn B, Corbett A, Pallesen S, Husebo BS. Joint occurrence of
pain and sleep disturbances in people with dementia. A systematic
review. Curr Alzheimer Res. 2017;14(5):538‐545.
9. Chen Q, Hayman LL, Shmerling RH, Bean JF, Leveille SG.
Characteristics of chronic pain associated with sleep difficulty in older
adults: the Maintenance of Balance, Independent Living, Intellect, and
Zest in the Elderly (MOBILIZE) Boston study. J Am Geriatr Soc. 2011;
59:1385‐1392.
10. Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J.
Sleep problems in a very old population: drug use and clinical
correlates. Biol Scien Med Scien. 2002;57:M236‐M240.
11. Stone K, Schneider JL, Blackwell T, et al. Impaired sleep increases the
risk of falls in older woman: a prospective actigraphy study. Sleep.
2004;27:A125
12. Widera E. What's to blame for falls and fractures? Poor sleep or
the sleeping medication? Comment on “Nonbenzodiazepine sleep
medication use and hip fractures in nursing home patients”. JAMA Intern
Med. 2013;173(9):761‐762.
13. Morley JE. Frailty, falls, and fractures. J Am Med Dir Assoc. 2013;
14:149‐151.
14. Dew MA, Hoch C, Buysse DJ, et al. Healthy older adults' sleep predicts
all‐cause mortality at 4 to 19 years of follow‐up. Psychosom Med.
2003;65(1):63‐73.
15. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive
functioning in older adults. J Am Geriatr Soc. 2001;49(9):1185‐1189.
16. Enache D, Winblad B, Aarsland D. Depression in dementia:
epidemiology, mechanisms, and treatment. Curr Opin Psychiatry. 2011;
24:461‐472.
17. Chopra K, Arora V. An intricate relationship between pain and
depression: clinical correlates, coactivation factors and therapeutic
targets. Expert Opin Ther Targets. 2014;18(2):159‐176.
670 BLYTT ET AL.18. Potter GG, Steffens DC. Contribution of depression to cognitive
impairment and dementia in older adults. Neurologist. 2007;
13(3):105‐117.
19. Ancoli‐Israel S, Cooke JR. Prevalence and comorbidity of insomnia and
effect on functioning in elderly populations. J Am Geriatr Soc. 2005;53(S7):
S264‐S271.
20. Buysse DJ, Reynolds CF, Hoch CC, et al. Rapid eye movement sleep
deprivation in elderly patients with concurrent symptoms of depression
and dementia. J Neuropsychiatry Clin Neurosci. 1991;4(3):249‐256.
21. Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in
dementia: a factor analysis of the neuropsychiatric inventory. Dement
Geriatr Cogn Dis. 2003;15(2):99‐105.
22. Morley E. Sleep and the nursing home. J Am Med Dir Assoc. 2015;
16:539‐543.
23. Sivertsen B, Lallukka T, Petrie KJ, Steingrímsdóttir ÓA, Stubhaug A,
Nielsen CS. Sleep and pain sensitivity in adults. Pain. 2015;156(8):
1433‐1439.
24. Husebo BS, Strand LI, Moe‐Nilssen R, Husebo SB, Ljunggren AE. Pain in
older persons with severe dementia. Psychometric properties of the
Mobilization‐Observation‐Behaviour‐Intensity‐Dementia (MOBID‐2)
Pain Scale in a clinical setting. Scand J Caring Sci. 2010;24(2):380‐391.
25. Husebo BS, Strand LI, Moe‐Nilssen R, Husebo SB, Snow AL, Ljunggren
AE. Mobilization‐Observation‐Behavior‐Intensity‐Dementia Pain Scale
(MOBID): development and validation of a nurse‐administered pain
assessment tool for use in dementia. J Pain Symptom Manage. 2007;
34(1):67‐80.
26. Husebo BS, Ballard C, Fritze F, Sandvik RK, Aarsland D. Efficacy of pain
treatment on mood syndrome in patients with dementia: a randomized
clinical trial. Int J Geriatr Psychiatry. 2013;29(8):828‐836.
27. Barca ML, Engedal K, Selbæk G. A reliability and validity study of the
Cornell scale among elderly inpatients, using various clinical criteria.
Dement Geriatr Cogn Dis. 2010;29(5):438‐447.
28. Tombaugh TN, McIntyre NJ. The Mini‐Mental State Examination: a
comprehensive review. J Am Geriatr Soc. 1992;40(9):922‐935.
29. Kukull WA, Larson EB, Teri L, Bowen J, McCormick W, Pfanschmidt
ML. The Mini‐Mental State Examination score and the clinical diagnosis
of dementia. J Clin Epidemiol. 1994;47(9):1061‐1067.
30. Lacks P, Morin CM. Recent advances in the assessment and treatment
of insomnia. J Consult Clin Psychol. 1992;60:58631. Sessums LL, Zembrzuska H, Jackson JL. Does this patient have medical
decision‐making capacity? JAMA. 2011;306(4):420‐427.
32. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of
treating pain to reduce behavioural disturbances in patients of nursing
homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:
d4065
33. Zanocchi M, Maero B, Nicola E, et al. Chronic pain in a sample of
nursing home residents: prevalence, characteristics, influence on
quality of life (QoL). Arch Gerontol Geriatr. 2008;47:121‐128.
34. McNicol E, Horowicz‐Mehler N, Fisk RA, et al. Management of opioid
side effects in cancer‐related and chronic noncancer pain: a systematic
review. J Pain. 2003;4(5):231‐256.
35. Camargos EF, Louzada FM, Nóbrega OT. Wrist actigraphy for
measuring sleep in intervention studies with Alzheimer's disease
patients: application, usefulness, and challenges. Sleep Med Rev.
2013;17(6):475‐488.
36. Feise RJ. Do multiple outcome measures require p‐value adjustment?
BMC Med Res Methodol. 2002;2(1):8
37. Marino M, Li Y, Rueschman MN, et al. Measuring sleep: accuracy,
sensitivity, and specificity of wrist actigraphy compared to
polysomnography. Sleep. 2013;36(11):1747‐1755.
38. Kushida CA, Chang A, Gadkary C, Guilleminault C, Carrillo O, Dement
WC. Comparison of actigraphic, polysomnographic, and subjective
assessment of sleep parameters in sleep‐disordered patients. Sleep
Med. 2001;2(5):389‐396.
39. Sivertsen B, Omvik S, Havik OE, et al. A comparison of actigraphy and
polysomnography in older adults. Sleep. 2006;29(10):1353‐1358.
40. Sandvik R, Selbaek G, Kirkevold O, Husebo BS, Aarsland D.
Analgesic prescribing patterns in Norwegian nursing homes from
2000 to 2011: trend analyses of four data samples. Age Ageing. 2016;
45:54‐60.
How to cite this article: Blytt KM, Bjorvatn B, Husebo B,
Flo E. Effects of pain treatment on sleep in nursing home
patients with dementia and depression: A multicenter
placebo‐controlled randomized clinical trial. Int J Geriatr
Psychiatry. 2018;33:663–670. https://doi.org/10.1002/gps.4839
